Siatis Perry C

EVP/GC Perry sold 18.7K shares ($4.4M) across 3 transactions at blended $234.39, reducing holdings by 80.2%

Siatis Perry C, serving as EVP, General Counsel and Secretary, executed three separate sales on 2026-03-02 totaling 18,668 shares for $4,375,549.33, reducing his holdings from 23,287 shares to 4,619 shares—an 80.2% reduction in position size. The execution prices ranged from $233.51 to $235.26, clustering tightly around the $234.39 blended average, slightly below the current price of $233.86. At ABBV specifically, Perry's prior four measurable sales (Feb–Mar 2025) all achieved negative 90-day returns ranging from -9.6% to -11.4%, establishing a 100% well-timed rate at this ticker; this new sale arrives near the 52-week high of $244.38 (only -4.3% back), presenting a structurally similar high-conviction-exit signal as his prior sales. The magnitude—an 80% portfolio reduction by a seated executive—combined with his demonstrated precision timing at this ticker warrants investor attention to potential forward-looking signals embedded in his exit.

EVP/GC Siatis Perry sells 22,381 shares of ABBV at $230.00 for $5.1M, reducing holdings 37% to 38.1K shares

Siatis Perry, EVP and General Counsel, executed a substantial open-market sale of 22,381 shares at $230.00, totaling $5,147,630.00 and reducing his holdings by 37% from 60,518 to 38,137 shares. His prior five trades at ABBV all showed negative 90-day returns averaging -10.0%, with a 100% well-timed rate at this ticker—a pattern consistent with his broader cross-ticker track record showing a 100% 90-day well-timed rate across 9 prior sells. At the current price of $232.08, the stock sits -5.0% from its 52-week high of $244.38, suggesting this sale occurred near elevated valuation within the recent trading range. The substantial reduction in a senior executive's concentrated position, combined with his demonstrated historical precision in sell timing, represents a material signal warranting attention to near-term valuation dynamics at AbbVie.

EVP/GC Siatis Perry sold 27,900 shares at blended avg $208.69, reducing holdings 85.8%, totaling $5.8M.

Siatis Perry C, EVP, General Counsel and Secretary at AbbVie, executed 4 separate sales totaling 27,900 shares for $5,822,401.63 over February 28 and March 3, 2025, reducing his holdings from 32,519 shares to 4,619 shares—a reduction of 85.8%. This substantial reduction occurred as the stock traded within 1.8% of its 52-week high ($211.48) and has appreciated 13.0% over the prior 30 days and 17.7% over the prior 90 days. Notably, Perry's prior 5 trades at ABBV all showed negative 90-day returns, with 3 of 3 measurable outcomes well-timed at the 90-day mark, suggesting a consistent pattern of selling ahead of subsequent declines at this ticker. The current near-peak pricing and strong recent momentum are contextual factors investors should monitor alongside the near-complete liquidation of his personal stake.

EVP/GC Siatis Perry sold 5,778 shares for $1,143,452.88 at blended avg $197.90; stock now $204.08

Siatis Perry C, EVP, General Counsel and Secretary, executed 2 separate sales totaling 5,778 shares for $1,143,452.88 on 2025-02-20, reducing holdings by 20.5% from 28,159 to 22,381 shares. The blended average price of $197.90 sits below the current price of $204.08, and the stock has rallied +19.8% over the past 30 days—within 0.0% of its 52-week high. His prior sales at ABBV show a consistent timing pattern: all 3 prior trades at this ticker were well-timed at the 90-day mark, with 90-day returns ranging from -10.8% to -13.1%, suggesting the insider has historically sold before subsequent declines. This filing provides a data point for tracking whether Perry's pattern continues, though the current momentum trajectory suggests near-term timing may differ from his historical average.